Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019

October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with...

COAPT Trial three-year data show the MitraClip continued effectiveness in heart failure patients with secondary mitral reguritation. #TCT2019 #TCT19 #mitralclip

COAPT Trial three-year data show the MitraClip continues to show safety and effectiveness in heart failure patients with secondary mitral reguritation.

News | Heart Failure | October 03, 2019

October 3, 2019 – The three-year results from the...

The Boston Scientiofic Acurate Neo TAVR valve did not meet non-inferiority to the Sapien 3 valve in patients with severe aortic stenosis. #TAVR #TCT2019
News | Heart Valve Technology | October 02, 2019

October 2, 2019 – The first randomized trial to compare the safety and efficacy of the new Boston Scientific Acurate...

The Portico FDA investigational device exemption (IDE) study found that 30-day safety and one-year effectiveness outcomes of a novel self-expanding transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis (AS) at high or extreme-risk for surgery was noninferior to contemporary FDA-approved TAVR systems. #TAVR #TCT2019
News | Heart Valve Technology | October 02, 2019

October 2, 2019 – The Abbott Portico FDA investigational device exemption (IDE) study found that 30-day safety and...

Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 30, 2019

September 30, 2019 – Data from the EVOLVE Short DAPT study found that shortened three-month...

Positive Safety, Efficacy Data Reported on AccuCinch Heart Failure Device
News | Heart Failure | September 27, 2019

September 27, 2019 — Ancora Heart Inc. announced results from an interim analysis of...

Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 26, 2019

September 26, 2019 — New data from the Phase IV independent TWILIGHT trial showed...

Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019

September 25, 2019 — Ten-year survival rates are similar for...

Videos | Hemodynamic Support Devices | September 22, 2019

There was a 77 percent increase in survival in cardiogenic shock patients treated using a new protocol in the...

Early ICD Use Prolongs Survival After Coronary Stenting
News | Implantable Cardioverter Defibrillator (ICD) | September 18, 2019

September 18, 2019 — Early use of an...

Rapid Diagnosis Protocol for Chest Pain Does Not Improve Outcomes
News | Blood Testing | September 18, 2019

September 18, 2019 — Discharge of patients with suspected acute coronary syndromes under a 0- and 1-hour...

Overlay Init